- Home
- NERV vs NBP Comparison
NERV vs NBP Comparison
Compare NERV & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | NBP |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.4M | 149.2M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NERV | NBP |
|---|---|---|
| Price | $2.31 | $1.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $10.33 | $9.00 |
| AVG Volume (30 Days) | 105.4K | ★ 698.2K |
| Earning Date | 11-04-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,175,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.24 | $1.26 |
| 52 Week High | $8.80 | $5.19 |
Technical Indicators
Market Signals| Indicator | NERV | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 27.35 | 43.17 |
| Support Level | N/A | $1.31 |
| Resistance Level | $5.69 | $1.44 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 4.83 | 46.34 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.